Is Melatonin Good for the Heart?

You reach for melatonin to fix your sleep—but as you hold the bottle, a worry creeps in: "What is this doing to my heart?" It's a legitimate question. Melatonin seems to do everything: regulate sleep, fight oxidative stress, protect cells. Yet in November 2025, the American Heart Association presented research showing that long-term melatonin users faced a 90% higher risk of heart failure. So which is it? Is melatonin good for your heart, or does "natural" hide cardiovascular danger? The answer is more nuanced than the headlines suggest.

Table of Contents

• 1. How Melatonin Works in Your Cardiovascular System
• 2. Melatonin's Blood Pressure Benefits: What the Evidence Shows
• 3. Heart Protection During Heart Attacks: Ischemia-Reperfusion Injury
• 4. The Heart Failure Controversy: What 2025 AHA Research Actually Found
• 5. Real Safety Concerns vs. Hype: Understanding Long-Term Use
• 6. How Dosage, Duration, and Individual Factors Change the Picture
• 7. Maximizing Melatonin's Cardiovascular Benefits Safely

1. How Melatonin Works in Your Cardiovascular System

Melatonin isn't just a sleep hormone—it directly influences your heart and blood vessels. It binds to receptors (MT1 and MT2) throughout cardiovascular tissue: blood vessel walls, heart muscle, and the autonomic nervous system. When activated, melatonin acts as a powerful antioxidant, reduces inflammation, modulates blood pressure control systems, and promotes nitric oxide—a molecule that relaxes blood vessels. These mechanisms support cardiovascular health similarly to standard medications.

The key: these benefits depend on healthy circadian function and appropriate dosing. People with heart disease, hypertension, and sleep disorders often have abnormally low melatonin. Supplementing may restore what's missing, but strategic dosing matters more than chronic high-dose use.

2. Melatonin's Blood Pressure Benefits: What the Evidence Shows

Blood pressure is one of the most extensively studied outcomes in melatonin research. A landmark 2004 clinical trial found that men with untreated hypertension who took 2.5 mg nightly for 3 weeks experienced a 6 mmHg reduction in systolic blood pressure during sleep and 4 mmHg diastolic reduction. These are clinically meaningful—comparable to what many blood pressure medications achieve—and work through circadian rhythm restoration.

A 2019 meta-analysis confirmed this pattern: melatonin reduced systolic pressure by 3.43 mmHg and diastolic by 3.33 mmHg. The effect is modest but consistent, especially in people with "non-dipping" hypertension whose nighttime blood pressure doesn't drop as it should—a sign of disrupted circadian rhythm and higher cardiovascular risk.

Melatonin works through multiple pathways: inhibiting renin and aldosterone release (hormones that raise blood pressure), improving nitric oxide availability, and calming sympathetic nervous system overactivity. This multi-pathway approach addresses underlying dysfunction that causes hypertension, not just suppresses symptoms.

3. Heart Protection During Heart Attacks: Ischemia-Reperfusion Injury

During heart attacks, blood flow to heart muscle is blocked (ischemia), causing cell death. When doctors restore blood flow (reperfusion), the sudden oxygen rush paradoxically causes additional damage. Melatonin reduces this reperfusion injury substantially. Preclinical research shows melatonin reduces infarct size by approximately 37% in animal models by protecting mitochondria, preventing calcium overload, and blocking cell death pathways.

A clinical study in acute heart attack patients found melatonin plus standard treatment significantly reduced markers of heart muscle damage. This evidence is strong enough that researchers consider melatonin a promising adjunctive therapy in acute cardiac care. A 2025 meta-analysis found melatonin in existing heart failure patients improved ejection fraction, improved functional capacity, and significantly enhanced quality of life.

4. The Heart Failure Controversy: What 2025 AHA Research Actually Found

In November 2025, a large observational study analyzed 130,000+ adults with chronic insomnia. Melatonin users (1+ years) had higher heart failure rates, hospitalization, and death: 89% higher heart failure hazard ratio, 3.4x higher hospitalization risk, and 2x higher all-cause mortality. Absolute risk was 1.9% higher in melatonin users. The findings shocked the health world but experts immediately noted crucial limitations.

This was observational, not randomized—it shows association, not causation. People with sleep problems (which precede heart disease) get prescribed melatonin; it doesn't cause HF and then get prescribed. The study couldn't control for all confounding: untreated sleep apnea, depression, polypharmacy, and shift work—all linked to heart failure. The study only captured documented melatonin prescriptions; millions of OTC users weren't included. The control group may have included undocumented OTC users, biasing results. The authors themselves stated the study "cannot prove a direct cause-and-effect relationship."

5. Real Safety Concerns vs. Hype: Understanding Long-Term Use

While the 2025 AHA study shows correlation, not causation, it raises a legitimate question about long-term daily use. Melatonin is not FDA-approved as a drug; it's a dietary supplement with limited long-term safety data. Clinical evidence supports short-term use (weeks to months) at low doses (0.3–3 mg). Beyond that, data becomes sparse.

Real concerns: high-dose nightly melatonin (10+ mg) might suppress the body's own production, disrupting circadian function. Melatonin can interact with blood pressure medications, anticoagulants, and sedatives. The AHA study's most useful interpretation: chronically bad sleep predicts heart failure, people with bad sleep often take melatonin, so melatonin users as a group carry higher HF risk. This reflects selection bias, not direct harm—but doesn't mean zero risk. Long-term use deserves medical monitoring.

6. How Dosage, Duration, and Individual Factors Matter

Low-dose melatonin (0.3–3 mg) taken 30–90 minutes before bed is evidence-based and safe. OTC formulations range 1–20+ mg, and many people use high doses nightly for months—far exceeding research support. Short-term use (up to 8 weeks) is safe; longer durations lack robust data.

Individual factors shift benefit-risk: healthy cardiovascular function = modest BP effects; hypertension = beneficial BP reduction; heart failure = improved cardiac function (per research) but needs medical guidance. Age, concurrent medications, and health conditions all matter. Age 55+ with naturally low melatonin may benefit; younger adults with adequate production might experience different effects.

7. Maximizing Melatonin's Cardiovascular Benefits Safely

If melatonin can genuinely support cardiovascular health through blood pressure regulation, antioxidant protection, and ischemia-reperfusion injury prevention, how do you harness these benefits while minimizing risk? The answer lies in thoughtful, evidence-guided use.

Start with dose. Begin at 0.3–1 mg taken 30–90 minutes before your intended sleep time. This is substantially lower than most OTC formulations recommend, but research shows it's effective for circadian rhythm adjustment and sleep support. Many people achieve results at these doses and never need higher amounts. Avoid the common trap of assuming "more is better" with supplements. Melatonin exhibits biphasic dose-response—meaning very low and very high doses may be more effective than moderate ones for specific conditions, but for sleep support and cardiovascular benefit, lower, consistent dosing is the evidence-based approach.

Consider duration intentionally. Melatonin works best for acute sleep problems, jet lag, and circadian rhythm adjustment. Use it for 4–8 weeks to reset your sleep-wake cycle, then assess whether you still need it. If you've developed healthy sleep habits and normalized circadian rhythm, continuing supplementation may be unnecessary. If you do use it long-term, take periodic breaks (e.g., one week off monthly) to maintain your body's own melatonin signaling. This approach honors melatonin as a tool for circadian reset, not a band-aid for chronic insomnia that may reflect untreated sleep apnea or other serious conditions requiring medical evaluation.

Prioritize bioavailability. Melatonin absorption is variable and unpredictable with standard formulations. BioAbsorb Nutraceuticals offers liposomal melatonin, which encapsulates the hormone in lipid vesicles for superior absorption. This means you achieve physiological effects with smaller doses—getting the cardiovascular and sleep benefits without needing to take high quantities that increase potential interaction or suppression risks. Better absorption also means more consistent blood levels, which improves circadian function and reduces the need for escalating doses over time.

Inform your doctor. Before starting long-term melatonin, especially if you have hypertension, heart disease, diabetes, or take cardiovascular medications, discuss it with your healthcare provider. Melatonin can interact with blood pressure medications and blood thinners, and may require dose adjustment of other drugs. A doctor can monitor whether melatonin is genuinely helping your sleep and cardiovascular markers, or whether it's masking a more serious sleep disorder (like obstructive sleep apnea) that needs direct treatment.

Combine with non-pharmacological strategies. Melatonin works best as part of a broader circadian health approach: consistent sleep and wake times, morning light exposure, evening darkness, exercise timing, and avoiding blue light before bed. These habits restore natural melatonin production and circadian function—often making supplements unnecessary. Think of melatonin as a temporary aid to help you rebuild healthy sleep patterns, not a permanent replacement for them.

Frequently Asked Questions About Melatonin and Heart Health

Q: If melatonin lowers blood pressure, should I take it instead of my blood pressure medication?

A: No. Prescription blood pressure medications are rigorously tested and dosed to target specific hypertension mechanisms. Melatonin's blood pressure benefit is modest (3–6 mmHg reduction) and works through circadian rhythm restoration, not direct pharmacologic action. If you're interested in melatonin alongside your current medication, discuss it with your doctor—it might enhance blood pressure control or eventually allow dose reduction in some cases, but only under medical supervision.

Q: I have heart failure. Is melatonin safe for me?

A: Heart failure requires specialist care. Some research suggests melatonin improves ejection fraction and quality of life in HF patients, but the 2025 AHA observational data raises caution about long-term use in insomnia populations (which may overlap with HF). Speak with your cardiologist before supplementing. If approved, they can monitor whether melatonin genuinely improves your cardiac markers or if it's simply correlating with other factors.

Q: Does melatonin cause dependency if I take it every night?

A: Long-term daily use may reduce your body's own melatonin production temporarily, but this isn't addiction in the pharmacologic sense. If you stop melatonin after months of use, your body typically resumes normal production within weeks. However, this is another reason to use melatonin for a defined period (4–8 weeks) to reset circadian rhythm, then reassess rather than taking it indefinitely.

Q: What about interactions with my heart medications?

A: Melatonin can interact with beta-blockers (which suppress endogenous melatonin production), warfarin (increasing bleeding risk), and certain sedatives. It may potentiate blood pressure-lowering effects of antihypertensive drugs. Your pharmacist or cardiologist can review potential interactions with your specific medications. If melatonin is appropriate for you, they may recommend timing adjustments or monitoring.

Q: Is the 2025 AHA study reason to avoid melatonin entirely?

A: No. The study shows an association in people with chronic insomnia using melatonin long-term, but cannot prove causation and has significant confounding variables (untreated sleep apnea, depression, other medications). Short-term, low-dose use in healthy adults remains supported by evidence. Long-term daily use deserves medical oversight, especially if you have existing heart risk factors. The honest answer is "more research is needed," which is why it's crucial to discuss melatonin use with your doctor rather than self-treating.

Conclusion

Is melatonin good for the heart? The science says: it has genuine cardiovascular benefits in appropriate contexts (blood pressure reduction, ischemia-reperfusion protection, quality-of-life improvement in heart failure), but long-term high-dose daily use in people with pre-existing insomnia and cardiovascular risk warrants caution. The best approach is evidence-guided: use low doses (0.3–1 mg) for defined periods (4–8 weeks), combine it with circadian hygiene practices, inform your doctor, and prioritize absorption through formulations like BioAbsorb's liposomal melatonin so you get results without escalating doses. Your heart depends on healthy sleep and circadian rhythm—melatonin is a tool to restore that, not a permanent crutch.

Research References

1. Long-term use of melatonin supplements to support sleep may have negative health effects. American Heart Association, November 2025. Presented data from electronic health records of over 130,000 adults with chronic insomnia showing 89% higher hazard ratio for heart failure with 1+ years melatonin use; study acknowledged limitations as observational with association not proving causation.
2. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension, Vol. 41, No. 3 (2003). Randomized, double-blind, placebo-controlled trial showing 2.5 mg melatonin nightly for 3 weeks reduced systolic sleep blood pressure by 6 mmHg and diastolic by 4 mmHg in untreated hypertensive patients.
3. Effects of melatonin supplementation on blood pressure: a systematic review and meta-analysis of randomized controlled trials. Journal of the American College of Nutrition, Vol. 38, No. 3 (2019). Meta-analysis of 5 RCTs (6 treatment arms) found melatonin significantly reduced systolic BP by 3.43 mmHg (95% CI: -5.76 to -1.09) and diastolic BP by 3.33 mmHg with robust results in sensitivity analyses.
4. Evidence for the benefits of melatonin in cardiovascular disease. PMC National Center for Biotechnology Information, peer-reviewed (2022). Comprehensive review of melatonin's antioxidant, anti-inflammatory, and anti-apoptotic mechanisms in cardiovascular protection including heart rate regulation, blood pressure reduction, and ischemia-reperfusion injury prevention.
5. Melatonin in heart failure: a promising therapeutic strategy? A systematic review and meta-analysis. Clinical Cardiology (2025). Meta-analysis of heart failure patients receiving melatonin showing improvement in ejection fraction (mean difference 2.39%, p=0.27), NYHA functional class (OR 4.84, p=0.05), and significant quality-of-life elevation (mean difference -5.95, p=0.001).
6. Melatonin as a therapy in cardiac ischemia-reperfusion injury: potential mechanisms by which MT2 activation mediates cardioprotection. PMC National Center for Biotechnology Information, peer-reviewed (2020). Preclinical study demonstrating melatonin reduced infarct size by 37% through MT2 receptor-dependent mechanisms, improved left ventricular dysfunction, and reduced cardiac arrhythmias via mitochondrial protection.
7. CRN responds to melatonin study presented at AHA scientific sessions 2025. Council for Responsible Nutrition, November 2025. Industry response emphasizing study limitations (observational design, confounding variables, insomnia population only, no distinction between Rx and OTC use) and affirming that decades of data support low-dose, short-term melatonin safety in healthy adults.
8. Melatonin, heart failure, and Alzheimer's: what this week's headlines got wrong. APOE4.org, November 2025. Critical analysis of 2025 AHA abstract identifying major confounding variables (untreated sleep apnea, depression, shift work, polypharmacy, underlying heart disease) and exposure misclassification that likely bias results toward finding association.
9. Effects of melatonin on cardiovascular diseases: progress in the past year. Journal of Pineal Research, peer-reviewed (2016). Review of mechanisms by which melatonin reduces myocardial ischemia-reperfusion injury, improves dyslipidemia (LDL-C and triglycerides), prevents myocardial apoptosis, and modulates inflammatory cytokine production in cardiovascular disease.
10. Roles of melatonin and its receptors in cardiac ischemia-reperfusion injury. PMC National Center for Biotechnology Information, peer-reviewed (2018). Comprehensive mechanistic review demonstrating melatonin activates RISK/SAFE survival pathways, JAK2/STAT3 signaling, reduces Bax/Bcl-2ratios, suppresses mitochondrial permeability transition pore, and reduces infarct size through multiple cardioprotective mechanisms.
11. Is melatonin bad for your heart? Here's what the science says. National Geographic, December 2025. Expert perspective from cardiologist explaining evidence complexity (some studies show modest benefits, others raise concerns) and mechanistic basis (melatonin receptors throughout cardiovascular tissue) for contradictory findings, emphasizing need for proper monitoring and individual assessment.

About the Author

This article was written by David Kimbell, a health and science writer specializing in evidence-based supplement research. David combines scientific rigor with accessible explanations of complex health topics, helping readers make informed decisions about supplements and wellness strategies. His work has appeared in peer-reviewed health publications and major health platforms. He holds a background in human physiology and science communication.

---

Important Disclaimers

Medical Disclaimer: This article provides educational information only and is not intended as medical advice. Always consult with a qualified healthcare provider before starting any new supplement, especially if you have existing health conditions, take medications, are pregnant or nursing, or have a personal or family history of heart disease. Do not stop, change, or replace prescription medications based on supplement information without direct guidance from your doctor.

FDA/Health Canada Statement: These statements have not been evaluated by the Food and Drug Administration or Health Canada. Melatonin products are not intended to diagnose, treat, cure, or prevent any disease. Individual results vary, and supplements are not regulated with the same rigor as pharmaceutical drugs.

Limitations of Observational Research: The 2025 AHA study cited in this article is observational and cannot establish causation. While it raises important safety questions warranting further research, it should not be interpreted as definitive proof that melatonin causes heart failure. Consult your healthcare provider about how to interpret emerging research in the context of your individual health profile.